Abstract
Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial. We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry. Most patients presented with high-risk clinical features. At transplant, 49% of patients were in CR, 32% in PR and 18% failed induction therapy; 53% received radiotherapy. After the transplant 75% of patients achieved CR. With a median follow-up of 52.5 months, the OS, PFS and DFS at 4 years from diagnosis were, respectively, 84%, 81% and 81% for the first CR patients and 49%, 42% and 82% for the induction failure (PR and refractory) patients. Disease progression was the main cause of death (79%). By multivariate survival analysis the tumour score, refractory disease at transplant and radiotherapy were independent variables associated with OS and PFS. Our experience, with a prolonged follow-up, shows that patients with PMBL presenting at diagnosis with high-risk features or PR response to induction therapy have an encouraging survival with frontline ASCT. However, patients who received the transplant after failing the induction regimen have a very poor prognosis and should...Continue Reading
References
Jan 1, 1977·British Journal of Cancer·R PetoP G Smith
Nov 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RodríguezJ Romaguera
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jul 1, 1996·The American Journal of Surgical Pathology·D Cazals-HatemJ Audouin
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U PopatK van Besien
Mar 28, 1998·Leukemia & Lymphoma·J E RomagueraF Cabanillas
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A Abou-ElellaJ O Armitage
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Apr 18, 2002·Bone Marrow Transplantation·R CairoliE Morra
Apr 19, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ConstansUNKNOWN GEL/TAMO Cooperative Group
Aug 23, 2003·Blood·Kerry J SavageMargaret A Shipp
Sep 17, 2003·The Journal of Experimental Medicine·Andreas RosenwaldLouis M Staudt
Jan 22, 2004·British Journal of Cancer·G TodeschiniG Pizzolo
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RodriguezE Conde
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnJoseph M Connors
Oct 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K J SavageJ M Connors
Citations
Jul 27, 2011·Current Oncology Reports·Pier Luigi Zinzani, Pier Paolo Piccaluga
Jun 22, 2014·Current Hematologic Malignancy Reports·Anna Dabrowska-Iwanicka, Jan A Walewski
Apr 15, 2014·Leukemia & Lymphoma·Chan Y CheahConstantine S Tam
Jan 26, 2011·Leukemia & Lymphoma·Wai Meng TaiSoon Thye Lim
Jun 28, 2011·Blood·Christian Steidl, Randy D Gascoyne
Mar 8, 2017·Blood·Pier Luigi ZinzaniVittorio Stefoni
Nov 26, 2016·Hematology·Xiaojian LiuXiaonan Hong
Jan 13, 2017·Hematological Oncology·Vitaliana De SanctisMaurizio Martelli
Apr 12, 2014·Blood Research·Heui June AhnCheolwon Suh
Feb 1, 2009·Expert Review of Hematology·Xavier Poiré, Koen van Besien
Dec 17, 2008·Hematology·Peter W M Johnson, Andrew J Davies
Nov 20, 2015·American Journal of Clinical Oncology·Bouthaina S DabajaLouis S Constine
Dec 30, 2014·Expert Review of Hematology·Maurizio MartelliRobin Foà
Apr 19, 2017·BMC Cancer·Alessandro BroccoliPier Luigi Zinzani
Jun 18, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Santosha VardhanaCraig H Moskowitz